niacin and Elevated Cholesterol studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Research Excerpts

Excerpt	Relevance	Reference
"To assess the effects of anacetrapib added to statin ± other lipid-modifying therapies in patients with hypercholesterolemia and not at their low-density lipoprotein cholesterol (LDL-C) goal (as per National Cholesterol Education Program Adult Treatment Panel III [NCEP ATP III] guidelines) and in those with low high-density lipoprotein cholesterol (HDL-C)."	9.24	Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. ( Ashraf, TB; Ballantyne, CM; Cressman, MD; Gill, GG; Hunter, JA; Johnson-Levonas, AO; Kher, U; Mitchel, YB; Shah, S, 2017)
"We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia."	9.08	Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. ( Goldberg, AC; Guyton, JR; Kreisberg, RA; O'Connor, CM; Sprecher, DL; Superko, HR, 1998)
"Wax-matrix niacin (Endur-acin) was shown to be effective and well tolerated for the pharmacological treatment of hypercholesterolemia."	9.07	Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin. ( Bae, CY; Fontaine, PL; Huang, ZQ; Keenan, JM; Myers, S; Ripsin, C; Wenz, JB, 1992)
"Niacin and lovastatin are both effective drugs for the treatment of hypercholesterolemia and are among the drugs of first choice recommended by the adult treatment panel."	9.07	Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. ( Dujovne, CA; Frost, PH; Greguski, RA; Illingworth, DR; Knopp, RH; Mitchel, YB; Stein, EA; Tun, P; Zupkis, RV, 1994)
"A double-blind, randomized study was undertaken to evaluate the efficacy and safety of fluvastatin as monotherapy and as combination therapy with niacin in the treatment of hypercholesterolemia refractory to diet."	9.07	Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. ( Amorosa, LF; Jacobson, TA, 1994)
" The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial, which compared combined niacin/simvastatin with simvastatin alone, failed to demonstrate an incremental benefit of niacin among patients with atherosclerotic CVD and on-treatment low-density lipoprotein cholesterol values <70 mg/dl, but this study had some limitations."	8.88	Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou ( Baer, JT; Blaha, MJ; Blumenthal, RS; Michos, ED; Sibley, CT, 2012)
"All children who received single-drug niacin treatment for severe hypercholesterolemia between 1980 and 1991."	7.68	Niacin treatment of hypercholesterolemia in children. ( Baker, AL; Colletti, RB; McAuliffe, TL; Neufeld, EJ; Newburger, JW; Roff, NK, 1993)
" He was receiving niacin therapy for hypercholesterolemia, and 16 hours earlier had ingested a large quantity of wine."	7.68	Delirium and lactic acidosis caused by ethanol and niacin coingestion. ( Bachhuber, BH; Schwab, RA, 1991)
"Niacin treatment in hypercholesterolemic patients caused a significant increase in HDL-C and apolipoprotein A1 levels, and a decrease in triglyceride levels."	6.78	Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. ( Cohen, R; Hamoud, S; Hassan, A; Hayek, T; Kaplan, M; Meilin, E; Torgovicky, R, 2013)
" Dose-response surfaces provide a practical guide for dose selection."	6.71	Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. ( Corbelli, J; Crouse, JR; Insull, W; McGovern, ME; Schrott, H; Thompson, P; Zieve, F, 2004)
"Four niacin treatment groups (daily doses of 2000, 1500, 1250, and 1000 mg) were compared with placebo- and diet-treated controls to determine side-effect profile and optimal range of efficacy."	6.67	Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. ( Fontaine, PL; Huang, ZQ; Keenan, JM; Myers, S; Ripsin, CM; Wenz, JB, 1991)
"Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels."	6.36	Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982)
"To assess the effects of anacetrapib added to statin ± other lipid-modifying therapies in patients with hypercholesterolemia and not at their low-density lipoprotein cholesterol (LDL-C) goal (as per National Cholesterol Education Program Adult Treatment Panel III [NCEP ATP III] guidelines) and in those with low high-density lipoprotein cholesterol (HDL-C)."	5.24	Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. ( Ashraf, TB; Ballantyne, CM; Cressman, MD; Gill, GG; Hunter, JA; Johnson-Levonas, AO; Kher, U; Mitchel, YB; Shah, S, 2017)
"Reduction in xanthomata was observed with cholesterol reduction."	5.24	Hypercholesterolemia. Use of niacin and niacin combinations in therapy. ( RIVIN, AU, 1962)
"An open-labeled randomized trial with parallel groups was carried out to study the effects of Dif1stat (Monascus purpureus-Linear aliphatic alcohols-Niacin) in the treatment of primary moderate hypercholesterolemia."	5.14	Combined treatment with Dif1stat and diet reduce plasma lipid indicators of moderate hypercholesterolemia more effectively than diet alone: a randomized trial in parallel groups. ( Bucci, A; Di Giacomo, S; Mazza, F; Perrone, G; Serra, M; Stefanutti, C; Vivenzio, A, 2009)
"We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia."	5.08	Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. ( Goldberg, AC; Guyton, JR; Kreisberg, RA; O'Connor, CM; Sprecher, DL; Superko, HR, 1998)
"Low-dose niacin is a promising addition to hydroxymethylglutaryl-coenzyme A reductase inhibitor therapy in the treatment of hypercholesterolemia in patients with diabetes mellitus."	5.08	Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. ( Fonseca, VA; Gardner, SF; Granberry, MC; Marx, MA; Skelton, DR; White, LM, 1997)
" Six hundred and twelve patients with postdiet LDL cholesterol (LDL-C) levels in the range of 190-230 mg/dl (or 160-230 mg/dl for those with coronary heart disease or two or more coronary risk factors) were randomized to a stepped-care regimen (initial treatment with niacin followed by other agents if needed) or to initial use of lovastatin, an HMG-CoA reductase inhibitor."	5.08	A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS). ( Benson, VV; Borok, GM; Dudl, RJ; Epstein, A; Epstein, RS; Heys, JF; Menzin, J; Oster, G; Quinn, V, 1995)
"Wax-matrix niacin (Endur-acin) was shown to be effective and well tolerated for the pharmacological treatment of hypercholesterolemia."	5.07	Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin. ( Bae, CY; Fontaine, PL; Huang, ZQ; Keenan, JM; Myers, S; Ripsin, C; Wenz, JB, 1992)
"A double-blind, randomized study was undertaken to evaluate the efficacy and safety of fluvastatin as monotherapy and as combination therapy with niacin in the treatment of hypercholesterolemia refractory to diet."	5.07	Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. ( Amorosa, LF; Jacobson, TA, 1994)
"Niacin and lovastatin are both effective drugs for the treatment of hypercholesterolemia and are among the drugs of first choice recommended by the adult treatment panel."	5.07	Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. ( Dujovne, CA; Frost, PH; Greguski, RA; Illingworth, DR; Knopp, RH; Mitchel, YB; Stein, EA; Tun, P; Zupkis, RV, 1994)
"Noxious adverse effects frequently limit patient acceptance of niacin and bile acid sequestrants (BAS), first-line agents in the management of hypercholesterolemia."	5.07	Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. ( Hartz, A; Hiatt, J; Schectman, G, 1994)
" The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial, which compared combined niacin/simvastatin with simvastatin alone, failed to demonstrate an incremental benefit of niacin among patients with atherosclerotic CVD and on-treatment low-density lipoprotein cholesterol values <70 mg/dl, but this study had some limitations."	4.88	Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou ( Baer, JT; Blaha, MJ; Blumenthal, RS; Michos, ED; Sibley, CT, 2012)
" Many of these patients, as well as persons at heightened risk for cardiovascular disease because of a range of heritable conditions (eg, familial hypercholesterolemia, familial combined hyperlipidemia), will undoubtedly require binary or ternary regimens involving statins in concert with niacin, fibric-acid derivatives, or bile acid resins."	4.81	Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. ( Jacobson, TA, 2001)
"The nonlinear dose-response relation of statins, bile acid sequestrants, and niacin and their additive LDL cholesterol-lowering effect when used together suggest a strategy for treating hypercholesterolemia that may optimize effectiveness while minimizing adverse effects and cost."	4.79	Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. ( Hiatt, J; Schectman, G, 1996)
"Niacin has been used for years to treat hypercholesterolemia, but may not be as beneficial as thought for patients at high risk of cardiovascular disease."	3.79	Do patients on statins also need niacin? ( Jones, KW, 2013)
"Fluvastatin, a new synthetic inhibitor of HMGCoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, has been studied in several models to examine its effects when used in combination with other lipid-modifying agents such as derivatives of fibric acid (bezafibrate), resins (cholestyramine), and niacin."	3.78	Fluvastatin in combination with other lipid-lowering agents. ( Jokubaitis, LA, 1996)
"To explore the effect of niacin on the serum adiponectin concentration in hypercholesterolemia rabbit and the adiponectin concentration secreted by adipocytes in normal rabbits."	3.74	[Effect of niacin on adiponectin levels in the adipocytes secretion in rabbits]. ( Dong, SZ; Li, J; Yang, J; Zhao, SP; Zhou, HN, 2007)
"This study first demonstrates that in rabbits, hypercholesterolemia, both diet- or genetically induced, can influence the enzyme activities of the tryptophan-nicotinic acid pathway leading to a decreased formation of nicotinic acid, and thus NAD."	3.72	Tryptophan metabolism along the kynurenine pathway in diet-induced and genetic hypercholesterolemic rabbits. ( Allegri, G; Bertazzo, A; Biasiolo, M; Caparrotta, L; Comai, S; Costa, CV; Ragazzi, E, 2004)
"All children who received single-drug niacin treatment for severe hypercholesterolemia between 1980 and 1991."	3.68	Niacin treatment of hypercholesterolemia in children. ( Baker, AL; Colletti, RB; McAuliffe, TL; Neufeld, EJ; Newburger, JW; Roff, NK, 1993)
"Hepatotoxicity is a potential side effect of niacin therapy for hypercholesterolemia, ranging from mild aminotransferase elevation to fulminant hepatic failure."	3.68	Transient focal hepatic defects related to sustained-release niacin. ( Lawrence, SP, 1993)
" He was receiving niacin therapy for hypercholesterolemia, and 16 hours earlier had ingested a large quantity of wine."	3.68	Delirium and lactic acidosis caused by ethanol and niacin coingestion. ( Bachhuber, BH; Schwab, RA, 1991)
"Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3."	2.79	Effects of extended-release niacin with laropiprant in high-risk patients. ( Armitage, J; Aung, T; Collins, R; Craig, M; Haynes, R; Hopewell, JC; Jiang, L; Landray, MJ; Parish, S; Tomson, J; Wallendszus, K, 2014)
"Niacin treatment in hypercholesterolemic patients caused a significant increase in HDL-C and apolipoprotein A1 levels, and a decrease in triglyceride levels."	2.78	Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. ( Cohen, R; Hamoud, S; Hassan, A; Hayek, T; Kaplan, M; Meilin, E; Torgovicky, R, 2013)
" Treatment-related adverse experiences (AEs) related to flushing, pruritis, rash, gastrointestinal upset and elevations in liver transaminases and fasting serum glucose occurred more frequently with ERN/LRPT added to statin vs."	2.75	Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. ( Ceska, R; Giezek, H; Gil-Extremera, B; Maccubbin, D; Mao, A; McCrary Sisk, C; Paolini, JF; Shah, S; Vandormael, K, 2010)
" These results demonstrate that laropiprant does not enhance in vivo platelet reactivity, either alone or in combination with niacin."	2.74	Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. ( Chao, A; Cote, J; Dishy, V; Gutierrez, M; Lai, E; Larson, P; Laterza, O; Lauring, B; Luo, WL; Patterson, J; Wagner, JA, 2009)
"Niacin has complementary lipid-modifying efficacy to statins and cardiovascular benefit, but is underutilised because of flushing, mediated primarily by prostaglandin D(2) (PGD(2))."	2.73	Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. ( Bays, HE; Betteridge, A; Elinoff, V; Elis, A; Kuznetsova, O; Maccubbin, D; Mitchel, Y; Olsson, AG; Paolini, JF; Pasternak, RC; Reyes, R; Sirah, W; Sisk, CM; Yu, Q, 2008)
" In conclusion, this study showed that NER/S provided additional clinically relevant improvements in multiple lipid parameters and was safe and well tolerated."	2.73	Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). ( Bajorunas, DR; Ballantyne, CM; Davidson, MH; Karas, RH; Keller, LH; McKenney, J, 2008)
"Hypercholesterolemia is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD)."	2.72	Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes? ( Smith, SC; Stouffer, GA; Zhou, R, 2021)
"We planned to carry out a pilot study to evaluate the efficacy and safety as an antihypercholesterolemic agent of a brand dietary supplement made of Monascus purpureus titrated extract, octacosanols and niacin on 111 Caucasian patients with low cardiovascular disease risk (<20% by Framingham algorithms), comparing them with the antihypercholesterolemic effect of a low dosage of Pravastatin on 20 subjects with similar risk profile."	2.71	Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. ( Brancaleoni, M; Cicero, AF; Donati, F; Laghi, L; Mino, M, 2005)
" Dose-response surfaces provide a practical guide for dose selection."	2.71	Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. ( Corbelli, J; Crouse, JR; Insull, W; McGovern, ME; Schrott, H; Thompson, P; Zieve, F, 2004)
"Niacin is a useful lipid-modifying drug because it (1) decreases low-density lipoprotein (LDL) cholesterol, total cholesterol, triglycerides, and lipoprotein(a), and (2) raises high-density lipoprotein (HDL) cholesterol."	2.69	Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. ( Goldberg, AC, 1998)
" The four groups of ten subjects received either placebo bid, chromium polynicotinate (Cr) 200 microg bid, grape seed extract (GSE) 100 mg bid, or a combination of Cr and GSE at the same dosage bid."	2.69	Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study. ( Bagchi, D; Bui, M; Echard, B; Myers, A; Preuss, HG; Talpur, N; Tutuncuoglu, SO; Wallerstedt, D, 2000)
" Systemic exposure is limited because of extensive sequestration by the liver and/or first-pass metabolism, a plasma half-life of approximately 30 min, no circulating active metabolites, and no accumulation of drug during chronic dosing."	2.67	Pharmacokinetics of fluvastatin and specific drug interactions. ( Hwang, DS; Jokubaitis, LA; Robinson, WT; Smith, HT; Troendle, AJ, 1993)
"To compare escalating doses of immediate-release (IR) and sustained-release (SR) niacin for effectiveness in reducing levels of low-density lipoprotein cholesterol and triglycerides and increasing levels of high-density lipoprotein cholesterol, and for the occurrence of adverse reactions, especially hepatotoxicity."	2.67	A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. ( Chinchili, VM; Harris, S; McKenney, JM; Proctor, JD, 1994)
"Fluvastatin, a new synthetic inhibitor of HMGCoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, has been studied in several models to examine its effects when used in combination with other lipid-modifying agents such as derivatives of fibric acid (bezafibrate), resins (cholestyramine), and niacin."	2.67	Fluvastatin in combination with other lipid-lowering agents. ( Jokubaitis, LA, 1994)
"Four niacin treatment groups (daily doses of 2000, 1500, 1250, and 1000 mg) were compared with placebo- and diet-treated controls to determine side-effect profile and optimal range of efficacy."	2.67	Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. ( Fontaine, PL; Huang, ZQ; Keenan, JM; Myers, S; Ripsin, CM; Wenz, JB, 1991)
"Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day)."	2.61	New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. ( Preston Mason, R, 2019)
" There is a clear dose-response effect of statin treatment on PCSK9 level, as increasing doses of statins also increase the level of circulating PCSK9."	2.55	Lipid Lowering Therapy and Circulating PCSK9 Concentration. ( Nozue, T, 2017)
"Niacin therapy was associated with a RR of 1."	2.53	Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. ( Goldie, C; McCoy, C; Nguyen, P; Preiss, D; Taylor, AJ; Zhao, XQ, 2016)
"Hypercholesterolemia is one of the main factors in the development of atherosclerotic cardiovascular disease."	2.47	The resurgence of niacin: from nicotinic acid to niaspan/laropiprant. ( Markel, A, 2011)
"Moreover, when hypercholesterolemia is associated with low concentrations of high-density lipoprotein (HDL)-cholesterol and high triglyceride levels, the association of statins with nicotinic acid, fibrates or omega-3 should be considered."	2.46	[Advances in cholesterol-lowering interventions]. ( Ascaso, JF, 2010)
" Many clinical trials have been designed to evaluate pharmacologic compounds in the treatment of the dyslipidemias and they seem to have shown a safe profile, both in the experiment phases and in post-marketing observation studies."	2.42	Hepatotoxicity of hypolipidemic drugs. ( Parra, JL; Reddy, KR, 2003)
"There is clear evidence that treating hypercholesterolemia reduces cardiovascular risk in women, as well as in men."	2.41	Management of hypercholesterolaemia in postmenopausal women. ( Davidson, MH; Ingram, KA; Karp, SK; Maki, KC, 2002)
" A myriad of studies that have examined efficacy, safety, adverse effects, and pharmacologic properties of niacin rendered convincing evidence that niacin, used alone or combined with other agents, has favorable effects on serum lipoprotein regulation and on containment of atherothrombotic cardiovascular diseases."	2.41	Niacin dosing: relationship to benefits and adverse effects. ( Brusco, OA; Capuzzi, DM; Intenzo, CM; Morgan, JM, 2000)
"Advances in treatment of elevated cholesterol levels and recent documentation of efficacy and safety in clinical trials justify expanded use of cholesterol-lowering therapy in clinical practice."	2.40	Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. ( Grundy, SM, 1997)
"Lovastatin (20 mg/d) was also efficient ($177 per percent reduction)."	2.38	Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. ( Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK, 1990)
"The surgical treatment of hypercholesterolemia and the treatment of homozygous and other forms of hypercholesterolemia are also detailed."	2.36	Treatment of hypercholesterolemia. ( Kane, JP; Malloy, MJ, 1982)
"Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels."	2.36	Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982)
"Ezetimibe is a lipid lowering medication that is able to inhibit dietary cholesterol."	1.36	Ezetimibe and recent clinical trials: a look on the bright side. ( Ahmed, MH, 2010)
" Aspirin was used by one third of patients before Niaspan dosing to minimize flushing episodes."	1.30	Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. ( Brody, J; Brusco, OA; Capuzzi, DM; Goldberg, AC; Guyton, JR; Kreisberg, RA; Morgan, JM, 1998)
"Would the money spent on treating hypercholesterolemia save more lives if spent elsewhere? How many dollars must be spent on a treatment to make one person live 1 year longer? This cost-effectiveness analysis uses the cost per year of life gained to compare a wide variety of health care interventions ranging from carcinogen research to screening tests to liver transplants."	1.28	Hypercholesterolemia: the cost of treatment in perspective. ( Kelley, MD, 1990)
"lovastatin therapy to lower plasma cholesterol does not lead to corresponding reductions in body cholesterol pools or to a reduction in the rate of whole-body cholesterol synthesis."	1.28	Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. ( Adams, M; Dell, RB; Goldberg, IJ; Goodman, DS; Holleran, S; Palmer, RH; Ramakrishnan, R, 1990)
"There are indications that treatment of hypercholesterolemia by means of drugs reduce risk of atherosclerosis in patients with increased concentrations of atherogenic lipoproteins."	1.28	[Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988]. ( Blomhoff, JP; Ose, L; Torsvik, H, 1989)
" Most of these drugs have side effects which, in the elderly, may necessitate lower dosing than usual."	1.27	Treating hyperlipidemia, Part III: Drug therapy. ( Brown, WV; Karmally, W; Smith, DA, 1987)
"Prophylactic treatment of the hyperlipoproteinemia with the drugs niceritrol (Perycit) and beta-pyridylcarbinol (Ronicol) significantly reduced the elevated plasma cholesterol level and reduced the degree of atherosclerosis in the abdominal aorta and the coronary arteries."	1.27	[Experimental hyperlipoproteinemia and arteriosclerosis in minipigs--effect of various drugs]. ( Jacobsson, L, 1986)
"Only lovastatin treatment was free of adverse effects."	1.27	Comparison of six pharmacologic regimens for hypercholesterolemia. ( Bailey, KR; Brewer, HB; Hoeg, JM; Maher, MB, 1987)
"Reduction in xanthomata was observed with cholesterol reduction."	1.24	Hypercholesterolemia. Use of niacin and niacin combinations in therapy. ( RIVIN, AU, 1962)

Research

Studies (241)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Coronary or Non-coronary Revascularisation

Timeframe	Studies, this research(%)	All Research%
pre-1990	92 (38.17)	18.7374
1990's	64 (26.56)	18.2507
2000's	43 (17.84)	29.6817
2010's	41 (17.01)	24.3611
2020's	1 (0.41)	2.80

Authors	Studies
Fenton, G	1
Newton, CG	1
Wyman, BM	1
Bagge, P	1
Dron, DI	1
Riddell, D	1
Jones, GD	1
Zhou, R	1
Stouffer, GA	1
Smith, SC	1
Nozue, T	1
Preston Mason, R	1
Ruscica, M	1
Pavanello, C	1
Gandini, S	1
Macchi, C	1
Botta, M	1
Dall'Orto, D	1
Del Puppo, M	1
Bertolotti, M	1
Bosisio, R	1
Mombelli, G	1
Sirtori, CR	1
Calabresi, L	1
Magni, P	1
Jones, KW	1
Wahawisan, J	1
Tovar, JM	1
Granberry, MC	2
Gudzune, KA	1
Monroe, AK	1
Sharma, R	1
Ranasinghe, PD	1
Chelladurai, Y	1
Robinson, KA	1
Lloyd-Jones, DM	1
Landray, MJ	2
Haynes, R	3
Hopewell, JC	1
Parish, S	1
Aung, T	1
Tomson, J	1
Wallendszus, K	1
Craig, M	1
Jiang, L	1
Collins, R	1
Armitage, J	2
Huynh, K	1
Rembold, CM	1
Meneses, F	1
Hu, M	1
Tomlinson, B	1
van den Oever, IA	1
Nurmohamed, MT	1
Lems, WF	1
Santos-Gallego, CG	1
Badimon, J	1
Mayer, L	1
Bloomfield, HE	1
Goldie, C	1
Taylor, AJ	1
Nguyen, P	1
McCoy, C	1
Zhao, XQ	2
Preiss, D	1
Rahimi, K	1
Grammer, T	1
Kleber, M	1
Silbernagel, G	1
Scharnagl, H	1
März, W	1
Collins, PD	1
Sattar, N	1
Nichols, GA	1
Reynolds, K	1
Olufade, T	1
Kimes, TM	1
O'Keeffe-Rosetti, M	1
Sapp, DS	1
Anzalone, D	1
Fortmann, SP	1
Ballantyne, CM	2
Shah, S	2
Kher, U	1
Hunter, JA	1
Gill, GG	1
Cressman, MD	1
Ashraf, TB	1
Johnson-Levonas, AO	1
Mitchel, YB	2
Felts, AS	1
Sanford, M	1
Curran, MP	1
Maccubbin, D	2
Bays, HE	1
Olsson, AG	2
Elinoff, V	1
Elis, A	1
Mitchel, Y	1
Sirah, W	1
Betteridge, A	1
Reyes, R	1
Yu, Q	1
Kuznetsova, O	1
Sisk, CM	1
Pasternak, RC	2
Paolini, JF	2
Jokubaitis, LA	5
Lahoz, C	1
Mostaza, JM	1
Lauring, B	1
Dishy, V	1
Luo, WL	1
Laterza, O	1
Patterson, J	1
Cote, J	1
Chao, A	1
Larson, P	1
Gutierrez, M	1
Wagner, JA	1
Lai, E	1
Stefanutti, C	1
Mazza, F	1
Vivenzio, A	1
Di Giacomo, S	1
Perrone, G	1
Serra, M	1
Bucci, A	1
Parhofer, KG	1
Mitka, M	1
Ahmed, MH	1
Ascaso, JF	1
Toutouzas, K	1
Drakopoulou, M	1
Skoumas, I	1
Stefanadis, C	1
Ceska, R	1
Gil-Extremera, B	1
Giezek, H	1
Vandormael, K	1
Mao, A	1
McCrary Sisk, C	1
Gupta, A	1
Guyomard, V	1
Zaman, MJ	1
Rehman, HU	1
Myint, PK	1
Lee, T	1
Doggrell, SA	1
Klose, G	1
Custodis, F	1
Laufs, U	1
Markel, A	1
Maningat, P	1
Breslow, JL	1
Einecke, D	1
Nicholls, SJ	1
Michos, ED	1
Sibley, CT	1
Baer, JT	1
Blaha, MJ	1
Blumenthal, RS	1
Hamoud, S	1
Kaplan, M	1
Meilin, E	1
Hassan, A	1
Torgovicky, R	1
Cohen, R	1
Hayek, T	1
Dänschel, W	1
Steinhagen-Thiessen, E	2
Buffleben, C	1
Pittrow, D	1
Hildemann, SK	1
Packard, C	1
Koeller, J	1
Talbert, RL	1
Nagai, Y	1
Yanagi, K	1
Yamashita, S	1
Takemura, K	1
Matsuzawa, Y	1
Spirn, MJ	1
Warren, FA	1
Guyer, DR	1
Klancnik, JM	1
Spaide, RF	1
Kastelein, J	1
Parra, JL	1
Reddy, KR	1
PARSONS, WB	7
ACHOR, RW	7
BERGE, KG	7
MCKENZIE, BF	2
BARKER, NW	3
O'REILLY, PO	1
EILERSEN, P	1
HOBOLTH, N	1
RIVIN, AU	2
ALTSCHUL, R	3
SMART, TA	1
CHRISTENSEN, NA	3
MASON, HL	3
KLOSTER, JH	1
LJUNGGREN, H	1
GRISSLER, J	1
PROBST, F	1
HOFFER, A	1
POWER, MH	1
GOLDNER, MG	1
DOAK, PB	1
NICHOLSON, GI	1
NORTH, JD	1
HEYDEN, S	1
FUMAROLA, D	1
GIORDANO, D	1
DE RINALDIS, P	1
BARNETT, AJ	1
CARSON, VJ	1
TRIBIANO, CW	1
SPENCER, JL	1
ZANETTI, ME	1
TENNENT, DM	1
ZELVELDER, WG	1
ZWEIFLER, AJ	1
HOOBLER, SW	1
BOOTSMA, BK	1
BURSTEIN, J	1
WIRKBERG, G	1
KESTERMANN, E	1
PAULI, H	1
KIMMERLING, HW	1
VASKO, J	1
YOUNGER, R	1
STEPHENSON, SE	1
NAVA-RIVERA, A	2
RODRIGUEZ-TRUJILLO, F	1
BERNALDIAZ, L	1
FITZGERALD, O	1
HEFFERNAN, A	1
BRENNAN, P	1
MULCAHY, R	1
FENNELLY, JJ	1
MCFARLANE, R	1
TROMOVITCH, TA	1
JACOBS, PH	1
KERN, S	1
ARTEAGA, A	1
DIAZ, F	1
TORRES, MC	2
NUNEZ, I	2
LANGE, K	1
MAHL, M	1
MARKIEWICZ, M	1
FAIVRE, G	1
GILGENKRANTZ, JM	1
CHERRIER, F	1
HENRY, C	1
SCHOEN, H	2
ZELLER, W	1
HENNING, N	1
MOSELEY, V	1
FINCH, JW	1
ARTEAGALLONA, A	1
DIAZGREZ, F	1
BLANKENHORN, DH	2
CHIN, HP	1
KLEBANOV, BM	1
OWEN, WR	1
KLEIN, L	1
MENESESHOYOS, J	1
STUETTGEN, G	1
LEUTIGER, H	1
GOLDSMITH, GA	1
WENNERBY, S	1
ROE, DA	1
LIPTON, P	1
MICHELS, JG	1
BRANDEL, E	1
MIALE, JP	1
KOTTKE, BA	1
BOLLMAN, JL	1
JUERGENS, JL	1
WILLIAMS, B	1
URUCHURTU, G	1
Camenga, D	1
Gill, JM	1
Insull, W	1
McGovern, ME	2
Schrott, H	1
Thompson, P	1
Crouse, JR	1
Zieve, F	1
Corbelli, J	1
Jones, PH	1
Schuster, H	1
Superko, HR	3
Raul, E	1
Garrett, B	1
Allegri, G	1
Ragazzi, E	1
Costa, CV	1
Caparrotta, L	1
Biasiolo, M	1
Comai, S	1
Bertazzo, A	1
Charlotte, N	1
Sani, M	1
Carlson, LA	1
Dunbar, RL	1
Rader, DJ	1
Cicero, AF	1
Brancaleoni, M	1
Laghi, L	1
Donati, F	1
Mino, M	1
Zambon, A	1
Brown, BG	2
Hokanson, JE	2
Motulsky, AG	1
Brunzell, JD	1
Vogt, A	1
Kassner, U	1
Hostalek, U	1
Peiter, A	1
Zhao, SP	3
Yang, J	3
Li, J	3
Dong, SZ	3
Wu, ZH	2
Zhou, HN	1
Abdel-Maksoud, M	1
Sazonov, V	1
Gutkin, SW	1
Davidson, MH	2
McKenney, J	1
Keller, LH	1
Bajorunas, DR	1
Karas, RH	1
Criscuoli, M	1
Renzetti, AR	1
Subissi, A	1
Stamler, J	1
Smith, SR	1
Glueck, CJ	1
Kane, JP	3
Malloy, MJ	2
Ginsberg, HN	1
Oster, G	2
Borok, GM	2
Menzin, J	2
Heys, JF	1
Epstein, RS	2
Quinn, V	2
Benson, VV	1
Dudl, RJ	2
Epstein, A	1
Jacobson, TA	5
Amorosa, LF	3
Chin, MM	1
Fromell, GJ	1
Probstfield, JL	1
Hunninghake, DB	2
Illingworth, DR	2
Stein, EA	2
Dujovne, CA	1
Frost, PH	1
Knopp, RH	3
Tun, P	1
Zupkis, RV	1
Greguski, RA	1
Stewart, BF	1
Hillger, LA	1
Sniderman, AD	1
Dowdy, A	1
Fisher, LD	1
Albers, JJ	1
Paterson, RW	1
Paat, JJ	1
Steele, GH	1
Hathaway, SC	1
Wong, JG	1
Schectman, G	5
Hiatt, J	5
Hartz, A	2
Smith, HT	1
Troendle, AJ	1
Hwang, DS	1
Robinson, WT	1
McKenney, JM	3
Proctor, JD	1
Harris, S	1
Chinchili, VM	1
Lasagna, L	1
Luria, MH	1
Sapoznikov, D	1
Heudebert, GR	1
Van Ruiswyk, J	1
Schwartz, ML	1
Lawrence, SP	1
Colletti, RB	1
Neufeld, EJ	1
Roff, NK	1
McAuliffe, TL	1
Baker, AL	1
Newburger, JW	1
Heyse, JF	1
Benson, V	1
Epstein, AM	1
Gorshkova, IN	1
Kiseleva, NG	1
Akhmedzhanov, NM	1
Perova, NV	1
Farmer, JA	1
Gotto, AM	2
Gardner, SF	1
Marx, MA	1
White, LM	1
Skelton, DR	1
Fonseca, VA	1
Preobrazhenskiĭ, VN	1
Matveev, AA	1
Grundy, SM	2
Callanan, D	1
Blodi, BA	1
Martin, DF	1
Sikand, G	1
Kashyap, ML	1
Yang, I	1
Guyton, JR	2
Goldberg, AC	3
Kreisberg, RA	2
Sprecher, DL	1
O'Connor, CM	1
Capuzzi, DM	2
Morgan, JM	2
Brusco, OA	2
Brody, J	1
Scheen, AJ	1
Gordon, BR	1
Saal, SD	1
Arntz, HR	1
Wunderlich, W	1
Schnitzer, L	1
Stern, R	1
Fischer, F	1
Agrawal, R	1
Linderer, T	1
Schultheiss, HP	1
Mack, WJ	2
LaBree, L	1
Liu, C	1
Selzer, RH	1
Hodis, HN	1
Lee, TH	1
Intenzo, CM	1
Chin-Dusting, JP	1
Shaw, JA	1
Preuss, HG	1
Wallerstedt, D	1
Talpur, N	1
Tutuncuoglu, SO	1
Echard, B	1
Myers, A	1
Bui, M	1
Bagchi, D	1
Maki, KC	1
Karp, SK	1
Ingram, KA	1
Jaconello, P	1
Mattiussi, AJ	1
Blais, D	1
Prihoda, JS	1
Walter, AA	1
Florkowski, CM	1
Cramb, R	1
Krauss, RM	1
Keenan, JM	2
Bae, CY	1
Fontaine, PL	2
Wenz, JB	2
Myers, S	2
Huang, ZQ	2
Ripsin, C	1
Morrow, JD	1
Prakash, C	1
Duckworth, TA	1
Zackert, WE	1
Blair, IA	1
Oates, JA	1
Roberts, LJ	1
Appeltauer, LC	1
Gorrell, RL	1
Retzlaff, BM	1
Dowdy, AA	1
Walden, CE	1
McCann, BS	1
Gey, G	1
Cooper, M	1
Kolman, BS	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526]	Phase 4	450 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Efficacy of Red Yeast Rice Based Nutraceutical (Monacolin K 10 mg/Dose) Plus Probiotic (Bifidobacterium Longum BB536 ®) in Patients With Moderate Hypercholesterolemia.[NCT02689934]		33 participants (Actual)	Interventional	2016-04-30	Completed
A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant[NCT00461630]	Phase 3	25,673 participants (Actual)	Interventional	2007-01-31	Completed
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients Wit[NCT01717300]	Phase 3	459 participants (Actual)	Interventional	2012-11-06	Completed
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia[NCT00269204]	Phase 3	1,620 participants (Actual)	Interventional	2005-12-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Hypercholesterolemia[NCT00769132]	Phase 1	26 participants (Actual)	Interventional	2007-08-03	Completed
A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Type 2 Diabetes[NCT00618995]	Phase 1	26 participants (Actual)	Interventional	2007-08-31	Completed
A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.[NCT00479388]	Phase 3	1,216 participants (Actual)	Interventional	2007-07-31	Completed
A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073]		79 participants (Actual)	Interventional	2009-10-31	Completed
Familial Atherosclerosis Treatment Study[NCT00000512]	Phase 3	146 participants (Actual)	Interventional	1984-01-31	Completed
A Pilot Study of the Safety, Efficacy, and Tolerability of Extended-Release Niacin (Niaspan) for the Treatment of Elevated Non-HDL Cholesterol and Elevated Triglycerides in HIV-Infected Subjects[NCT00046267]		30 participants	Interventional		Completed
Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST[NCT00082251]	Phase 3	0 participants	Interventional		Completed
HDL Increased Plaque Stabilization in the Elderly[NCT00127218]	Phase 3	145 participants (Actual)	Interventional	2003-09-30	Completed
Correlates of Angiographic Changes and Coronary Events: The Cholesterol-Lowering Atherosclerosis Study (CLAS)[NCT00005433]		188 participants (Actual)	Observational	1996-04-30	Completed
[NCT00000599]	Phase 3	0 participants	Interventional	1980-06-30	Completed
ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)[NCT00397657]	Phase 4	400 participants (Anticipated)	Interventional	2006-11-30	Terminated (stopped due to Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

(NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Major Coronary Events

Intervention	participants (Number)
ER Niacin/Laropiprant	807
Placebo	897

Non-fatal myocardial infarction (MI) or coronary death (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Major Vascular Event

Intervention	participants (Number)
ER Niacin/Laropiprant	668
Placebo	694

Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Mortality

Intervention	participants (Number)
ER Niacin/Laropiprant	1696
Placebo	1758

All-cause mortality (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Stroke

Intervention	participants (Number)
ER Niacin/Laropiprant	798
Placebo	732

Fatal or non-fatal (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Prostaglandin I Metabolite (PGI-M)

Intervention	participants (Number)
ER Niacin/Laropiprant	498
Placebo	499

The creatinine-normalized urine levels of PGI-M in the overall 24 hour collection interval following administration on Day 7. (NCT00769132)
Timeframe: On Day 7 across the 24-hour urinary collection period.

Urinary 11-dehydrothromboxane B2 (11-dTxB2)

Intervention	pg/mg creatinine (Least Squares Mean)
ER Niacin 2 g / Laropiprant 40 mg	73.5
ER Niacin 2 g	70.9
Laropiprant 40 mg	114.5
Placebo	127.5

The creatinine-normalized urine levels of 11-dTxB2 on Day 7 following a 7 day course of daily dosing in the overall 24 hour collection interval. (NCT00769132)
Timeframe: On Day 7 across the 24-hour urinary collection period.

Prostaglandin I Metabolite (PGI-M)

Intervention	pg/mg creatinine (Least Squares Mean)
ER Niacin 2 g / Laropiprant 40 mg	414.6
ER Niacin 2 g	371.6
Laropiprant 40 mg	407.3
Placebo	466.1

PGI-M in the Overall 24 Hour Collection Interval Following Administration on Day 7 (NCT00618995)
Timeframe: On Day 7 across the 24-hour urinary collection period.

Urinary 11-Dehydrothromboxane B2 (11-dTxB2)

Intervention	pg/mg creatinine (Least Squares Mean)
ER Niacin/Laropiprant	90.1
ER Niacin	95.4
Laropiprant	158.5
Placebo	168.1

The creatinine-normalized urine levels of 11-dTxB2 on Day 7 following a 7 day course of daily dosing in the overall 24 hour collection interval (NCT00618995)
Timeframe: On Day 7 across the 24-hour urinary collection period.

Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12

Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12

Percent Change From Baseline in Triglycerides at Week 12

Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries

Intervention	pg/mg creatinine (Least Squares Mean)
ER Niacin/Laropiprant	525.3
ER Niacin	540.8
Laropiprant	585.3
Placebo	625.1

Intervention	Percent (Least Squares Mean)
ER Niacin/Laropiprant + Run-in Statin	15.8
Run-in Statin Dose Doubled	0.2

Intervention	Percent (Least Squares Mean)
ER Niacin/Laropiprant + Run-in Statin	-10.0
Run-in Statin Dose Doubled	-5.5

Intervention	Percent (Median)
ER Niacin/Laropiprant + Run-in Statin	-17.6
Run-in Statin Dose Doubled	-4.0

The primary endpoint is Changes in plaque architecture and composition directly measured by magnetic resonance imaging (MRI) in the aorta and carotid arteries. (NCT00127218)
Timeframe: 18 months

Multiple Combined Events ( Cardiovascular and Cerebrovascular Events as Well as Myocardial Revascularization)

Intervention	percentage of internal carotid artery (Mean)
Niacin Plus Statin	7
Placebo Plus Statin	5

Cerebrovascular events (newly diagnosed) such as Stroke and Myocardial revascularization (specifically coronary artery bypass grafting, percutaneous coronary interventions, carotid endarterectomy) were recorded (NCT00127218)
Timeframe: 18 months

Intervention	Participants (Count of Participants)
Any Statin Plus Niacin	6
Any Statin Plus Placebo	2

Article	Year
Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes? Journal of cardiovascular pharmacology and therapeutics, 2021, Volume: 26, Issue:6 Topics: Atherosclerosis; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hy	2021
Lipid Lowering Therapy and Circulating PCSK9 Concentration. Journal of atherosclerosis and thrombosis, 2017, Sep-01, Volume: 24, Issue:9 Topics: Antibodies, Monoclonal; Biomarkers; Cholesterol, LDL; Ezetimibe; Fibric Acids; Gene Silencing; Human	2017
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. Current atherosclerosis reports, 2019, 01-12, Volume: 21, Issue:1 Topics: Atherosclerosis; Cell Membrane; Cholesterol, LDL; Coronary Thrombosis; Docosahexaenoic Acids; Eicosa	2019
Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Annals of internal medicine, 2014, Apr-01, Volume: 160, Issue:7 Topics: Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Coronary Artery Diseas	2014
Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart (British Cardiac Society), 2016, Volume: 102, Issue:3 Topics: Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reduc	2016
Glycaemic Effects of Non-statin Lipid-Lowering Therapies. Current cardiology reports, 2016, Volume: 18, Issue:12 Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabeti	2016
Niacin extended-release/simvastatin. Drugs, 2008, Volume: 68, Issue:16 Topics: Animals; Clinical Trials as Topic; Drug Combinations; Flushing; Humans; Hydroxymethylglutaryl-CoA Re	2008
[HDL-cholesterol: from risk factor to therapeutic target]. Medicina clinica, 2009, Jul-11, Volume: 133, Issue:6 Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Humans; Hypercholesterolemia; Niacin; Ris	2009
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vascular health and risk management, 2009, Volume: 5 Topics: Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Flushing; Humans;	2009
[Advances in cholesterol-lowering interventions]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2010, Volume: 57, Issue:5 Topics: Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterole	2010
Advancing therapy for hypercholesterolemia. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10 Topics: Azetidines; Bile Acids and Salts; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins	2010
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. Advances in therapy, 2010, Volume: 27, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combinat	2010
Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011? Complementary therapies in medicine, 2011, Volume: 19, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; D	2011
[Hypertricglyceridemia: prognostic impact and treatment options]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:30 Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diet, R	2011
The resurgence of niacin: from nicotinic acid to niaspan/laropiprant. The Israel Medical Association journal : IMAJ, 2011, Volume: 13, Issue:6 Topics: Cholesterol; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Hypolipidemic Agents; I	2011
Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou Journal of the American College of Cardiology, 2012, Jun-05, Volume: 59, Issue:23 Topics: Aged; Cardiovascular Diseases; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up	2012
Management of hypercholesterolaemia in the patient with diabetes. International journal of clinical practice. Supplement, 2002, Issue:130 Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, T	2002
Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk. Pharmacotherapy, 2002, Volume: 22, Issue:10 Topics: Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-C	2002
[Treatment of high blood cholesterol in patients with coronary heart disease]. Nihon rinsho. Japanese journal of clinical medicine, 1994, Volume: 52 Suppl, Issue:Pt 1 Topics: Anion Exchange Resins; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethy	1994
What future for combination therapies? International journal of clinical practice. Supplement, 2003, Issue:134 Topics: Bile Acids and Salts; Clofibric Acid; Drug Therapy, Combination; Fish Oils; Forecasting; Humans; Hyp	2003
Hepatotoxicity of hypolipidemic drugs. Clinics in liver disease, 2003, Volume: 7, Issue:2 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Female; F	2003
[DRUGS LOWERING THE CHOLESTEROL LEVEL IN THE BLOOD]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1963, Sep-16, Volume: 18 Topics: Antimetabolites; Arteriosclerosis; Ascorbic Acid; Cholesterol; Choline; Corrinoids; Ethyl Biscoumace	1963
THE INTERRELATIONS BETWEEN CHOLESTEROL AND OTHER LIPIDS. II. A REVIEW. Journal of the South Carolina Medical Association, 1964, Volume: 60 Topics: Arteriosclerosis; Cholesterol; Edetic Acid; Estrogens; Fats, Unsaturated; Heparin; Humans; Hyperchol	1964
EFFICACY OF DRUGS IN LOWERING BLOOD CHOLESTEROL. The Medical clinics of North America, 1964, Volume: 48 Topics: Cholesterol; Diet; Diet Therapy; Estrogens; Estrogens, Conjugated (USP); Fats, Unsaturated; Humans;	1964
CUTANEOUS EFFECTS OF HYPOCHOLESTEREMIC AGENTS. New York state journal of medicine, 1964, Oct-15, Volume: 64 Topics: Anticholesteremic Agents; Drug Eruptions; Hypercholesterolemia; Ion Exchange Resins; Ketones; Niacin	1964
Improving lipid management--to titrate, combine or switch. International journal of clinical practice, 2004, Volume: 58, Issue:7 Topics: Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Red	2004
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. Journal of internal medicine, 2005, Volume: 258, Issue:2 Topics: Adipose Tissue; Arteriosclerosis; Coronary Disease; Fatty Acids, Nonesterified; Fibrinolysis; Flushi	2005
Demystifying triglycerides: a practical approach for the clinician. Cleveland Clinic journal of medicine, 2005, Volume: 72, Issue:8 Topics: Arteriosclerosis; Clofibric Acid; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors;	2005
Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:4 Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Diabetes Complications; Humans	2008
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis. Circulation, 1984, Volume: 69, Issue:5 Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl	1984
Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. Annals of internal medicine, 1982, Volume: 96, Issue:4 Topics: Arteriosclerosis; Cholesterol; Colestipol; Drug Therapy, Combination; Humans; Hypercholesterolemia;	1982
Treatment of hypercholesterolemia. The Medical clinics of North America, 1982, Volume: 66, Issue:2 Topics: Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Heterozygote; Homozygote; Humans; Hyper	1982
Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens. Clinical cardiology, 1995, Volume: 18, Issue:6 Topics: Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Coronary Disease; Drug Therapy, Combinat	1995
Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications. Southern medical journal, 1994, Volume: 87, Issue:2 Topics: Angiography; Clinical Trials as Topic; Colestipol; Coronary Disease; Humans; Hypercholesterolemia; L	1994
Fluvastatin in combination with other lipid-lowering agents. British journal of clinical practice. Supplement, 1996, Volume: 77A Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Dru	1996
Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Annals of internal medicine, 1996, Dec-15, Volume: 125, Issue:12 Topics: Anticholesteremic Agents; Bile Acids and Salts; Dose-Response Relationship, Drug; Drug Therapy, Comb	1996
Choosing the right lipid-regulating agent. A guide to selection. Drugs, 1996, Volume: 52, Issue:5 Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrat	1996
Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. Postgraduate medicine, 1997, Volume: 102, Issue:2 Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Longevity; Lovastatin; Nia	1997
Niacin dosing: relationship to benefits and adverse effects. Current atherosclerosis reports, 2000, Volume: 2, Issue:1 Topics: Anticholesteremic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hyper	2000
Lipids and atherosclerosis: clinical management of hypercholesterolaemia. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:3 Topics: Arteriosclerosis; Cholestyramine Resin; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA	2001
Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. Current atherosclerosis reports, 2001, Volume: 3, Issue:5 Topics: Coronary Disease; Drug Interactions; Drug Therapy, Combination; Humans; Hypercholesterolemia; Hyperl	2001
Lipid management: tools for getting to the goal. The American journal of managed care, 2001, Volume: 7, Issue:9 Suppl Topics: Anticholesteremic Agents; Bile Acids and Salts; Cholesterol; Drug Therapy, Combination; Humans; Hype	2001
Management of hypercholesterolaemia in postmenopausal women. Drugs & aging, 2002, Volume: 19, Issue:3 Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diet; Drug The	2002
Drug therapy of hyperlipidemia. Current problems in cardiology, 1992, Volume: 17, Issue:9 Topics: Anticholesteremic Agents; Butyrates; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination;	1992
Therapeutic intervention for hypercholesterolemia. Clinical cardiology, 1992, Volume: 15, Issue:11 Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Life Style; Niacin	1992
Approaches to the management of hypercholesterolaemia. Journal of clinical pharmacy and therapeutics, 1992, Volume: 17, Issue:2 Topics: Bezafibrate; Bile Acids and Salts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperchol	1992
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA, 1990, Dec-19, Volume: 264, Issue:23 Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit A	1990
Management of hyperlipidemia of kidney disease. Kidney international, 1990, Volume: 37, Issue:3 Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolem	1990
Current approaches to drug therapy for the hypercholesterolemic patient. Circulation, 1989, Volume: 80, Issue:5 Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-C	1989
New approaches to cholesterol lowering: efficacy and safety. Hospital practice (Office ed.), 1988, Volume: 23 Suppl 1 Topics: Anticholesteremic Agents; Cholesterol; Dietary Fats; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Re	1988
When to treat hyperlipidemia. Advances in internal medicine, 1988, Volume: 33 Topics: Animals; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H	1988
Treatment of hypercholesterolemia. Annual review of medicine, 1986, Volume: 37 Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination;	1986

Article	Year
Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study. Nutrition journal, 2019, 02-22, Volume: 18, Issue:1 Topics: Adult; Bifidobacterium longum; Biological Products; Cardiovascular Diseases; Dietary Supplements; Do	2019
Effects of extended-release niacin with laropiprant in high-risk patients. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Aged; Atherosclerosis; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus; Double-Blin	2014
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. The American journal of cardiology, 2017, Feb-01, Volume: 119, Issue:3 Topics: Aged; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol,	2017
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International journal of clinical practice, 2008, Volume: 62, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Blind Method; Drug C	2008
Fluvastatin in combination with other lipid-lowering agents. British journal of clinical practice. Supplement, 1994, Issue:77 Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Dru	1994
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. Journal of clinical pharmacology, 2009, Volume: 49, Issue:12 Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation	2009
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. Journal of clinical pharmacology, 2009, Volume: 49, Issue:12 Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation	2009
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. Journal of clinical pharmacology, 2009, Volume: 49, Issue:12 Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation	2009
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. Journal of clinical pharmacology, 2009, Volume: 49, Issue:12 Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation	2009
Combined treatment with Dif1stat and diet reduce plasma lipid indicators of moderate hypercholesterolemia more effectively than diet alone: a randomized trial in parallel groups. Lipids, 2009, Volume: 44, Issue:12 Topics: Administration, Oral; Body Mass Index; Diet; Female; Humans; Hypercholesterolemia; Hypolipidemic Age	2009
Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International journal of clinical practice, 2010, Volume: 64, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Dos	2010
Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. The American journal of the medical sciences, 2013, Volume: 345, Issue:3 Topics: Apolipoprotein A-I; C-Reactive Protein; Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Hypo	2013
Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice. Current medical research and opinion, 2013, Volume: 29, Issue:1 Topics: Age Factors; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Disease	2013
Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Archives of internal medicine, 2004, May-24, Volume: 164, Issue:10 Topics: Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrat	2004
Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I. The American journal of cardiology, 2004, Sep-01, Volume: 94, Issue:5 Topics: Adult; Aged; Delayed-Action Preparations; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents	2004
Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complementary therapies in medicine, 2005, Volume: 13, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Capsules; Cardiovascular Diseases; Dietary Supplements; Fatty	2005
Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy. Journal of internal medicine, 2006, Volume: 259, Issue:4 Topics: Adult; Analysis of Variance; Apolipoproteins B; Colestipol; Coronary Angiography; Coronary Stenosis;	2006
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). The American journal of cardiology, 2008, May-15, Volume: 101, Issue:10 Topics: Administration, Oral; Adult; Aged; Cholesterol, HDL; Delayed-Action Preparations; Dose-Response Rela	2008
Pharmacological trials: primary and secondary prevention of coronary heart disease. Preventive medicine, 1983, Volume: 12, Issue:1 Topics: Aspirin; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Colestipol; Coronary Disease; D	1983
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS). Controlled clinical trials, 1995, Volume: 16, Issue:1 Topics: Adult; Aged; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Fol	1995
Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. The American journal of medicine, 1994, Jun-06, Volume: 96, Issue:6A Topics: Anticholesteremic Agents; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Monounsaturat	1994
Fluvastatin with and without niacin for hypercholesterolemia. The American journal of cardiology, 1994, Jul-15, Volume: 74, Issue:2 Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Cholestero	1994
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Archives of internal medicine, 1994, Jul-25, Volume: 154, Issue:14 Topics: Adult; Aged; Female; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Ag	1994
Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. Journal of the American College of Cardiology, 1994, Mar-15, Volume: 23, Issue:4 Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Cholesterol, LDL; Colestip	1994
Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. The Annals of pharmacotherapy, 1994, Volume: 28, Issue:1 Topics: Allied Health Personnel; Anticholesteremic Agents; Female; Hospitals, Veterans; Humans; Hypercholest	1994
Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. The American journal of cardiology, 1994, May-26, Volume: 73, Issue:14 Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Drug Therapy, Combination; Fatty Acids,	1994
Pharmacokinetics of fluvastatin and specific drug interactions. American journal of hypertension, 1993, Volume: 6, Issue:11 Pt 2 Topics: Adolescent; Adult; Aged; Aging; Biological Availability; Cholestyramine Resin; Diet; Digoxin; Dose-R	1993
A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA, 1994, Mar-02, Volume: 271, Issue:9 Topics: Adult; Capsules; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Metho	1994
Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Archives of internal medicine, 1996, Apr-08, Volume: 156, Issue:7 Topics: Adult; Aged; Anticholesteremic Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hum	1996
Fluvastatin in combination with other lipid-lowering agents. British journal of clinical practice. Supplement, 1996, Volume: 77A Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Dru	1996
Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. The Annals of pharmacotherapy, 1997, Volume: 31, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 1; D	1997
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. The American journal of cardiology, 1998, Sep-15, Volume: 82, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr	1998
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. The American journal of cardiology, 1998, Sep-15, Volume: 82, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr	1998
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. The American journal of cardiology, 1998, Sep-15, Volume: 82, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr	1998
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. The American journal of cardiology, 1998, Sep-15, Volume: 82, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr	1998
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. The American journal of cardiology, 1998, Sep-15, Volume: 82, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr	1998
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. The American journal of cardiology, 1998, Sep-15, Volume: 82, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr	1998
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. The American journal of cardiology, 1998, Sep-15, Volume: 82, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr	1998
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. The American journal of cardiology, 1998, Sep-15, Volume: 82, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr	1998
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. The American journal of cardiology, 1998, Sep-15, Volume: 82, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Delayed-Action Preparations; Drug Administration Schedule; Dr	1998
Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. The American journal of cardiology, 1998, Dec-17, Volume: 82, Issue:12A Topics: Adult; Aged; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Hypercho	1998
[Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study]. Zeitschrift fur Kardiologie, 1999, Volume: 88, Issue:8 Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol	1999
Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Atherosclerosis, 2000, Volume: 150, Issue:2 Topics: Adult; Carotid Artery, Common; Carotid Stenosis; Colestipol; Coronary Angiography; Coronary Artery D	2000
Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study. Journal of medicine, 2000, Volume: 31, Issue:5-6 Topics: Analysis of Variance; Anthocyanins; Antioxidants; Blood Pressure; Cholesterol; Cholesterol, HDL; Cho	2000
Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin. Journal of the American Geriatrics Society, 1992, Volume: 40, Issue:1 Topics: Adult; Aged; Aging; Alkaline Phosphatase; Blood Glucose; Delayed-Action Preparations; Double-Blind M	1992
Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Archives of internal medicine, 1991, Volume: 151, Issue:7 Topics: Adult; Aged; Chemistry, Pharmaceutical; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholest	1991
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA, 1990, Dec-19, Volume: 264, Issue:23 Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination;	1990
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA, 1990, Dec-19, Volume: 264, Issue:23 Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination;	1990
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA, 1990, Dec-19, Volume: 264, Issue:23 Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination;	1990
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA, 1990, Dec-19, Volume: 264, Issue:23 Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination;	1990
[Effects on lipid metabolism of inhibitors of cholesterol synthesis]. La Clinica terapeutica, 1988, Apr-15, Volume: 125, Issue:1 Topics: Aged; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Clofibrate; Double-Blind Meth	1988

Article	Year
Hypolipidemic 2-[4-(1,1-dimethylethyl)phenyl]-4H-3,1-benzoxazin-4-ones. Structure-activity relationships of a novel series of high-density lipoprotein elevators. Journal of medicinal chemistry, 1989, Volume: 32, Issue:1 Topics: Animals; Chemical Phenomena; Chemistry; Cholesterol; Cholesterol, HDL; Hypercholesterolemia; Hypolip	1989
Do patients on statins also need niacin? JAAPA : official journal of the American Academy of Physician Assistants, 2013, Volume: 26, Issue:7 Topics: Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-	2013
Statin therapy: when to think twice. The Journal of family practice, 2013, Volume: 62, Issue:12 Topics: Cardiovascular Diseases; Contraindications; Drug Therapy, Combination; Heart Failure; Humans; Hydrox	2013
Niacin and HDL cholesterol--time to face facts. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Dyslipidaemia: Niacin-laropiprant fails to reduce the risk of vascular events. Nature reviews. Cardiology, 2014, Volume: 11, Issue:10 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
ACP Journal Club: adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events. Annals of internal medicine, 2014, Nov-18, Volume: 161, Issue:10 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin: old habits die hard. Heart (British Cardiac Society), 2016, Volume: 102, Issue:3 Topics: Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyp	2016
[Residual risk: The roles of triglycerides and high density lipoproteins]. Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:12 Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Fibric Acids	2016
Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus. The American journal of cardiology, 2017, Feb-01, Volume: 119, Issue:3 Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus,	2017
[Treatment of dyslipoproteinemia risk factor. Lipid therapy must become multidimensional]. MMW Fortschritte der Medizin, 2008, Jun-26, Volume: 150, Issue:26-27 Topics: Cerebral Infarction; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Humans; H	2008
Molecule of the Month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides. Current topics in medicinal chemistry, 2008, Volume: 8, Issue:14 Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Hypercholesterolemia; Indoles; N	2008
Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit. JAMA, 2010, Jan-20, Volume: 303, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; C	2010
Ezetimibe and recent clinical trials: a look on the bright side. Expert opinion on drug safety, 2010, Volume: 9, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-	2010
Nicotinic acid + larodiorant. Laropiprant adds its own adverse effects. Prescrire international, 2010, Volume: 19, Issue:105 Topics: Drug Combinations; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Preg	2010
Ask the doctor. I have tried all of the statin drugs to lower my cholesterol, but each one has caused severe muscle pain. Are there any non-statin medications I could try using to lower my cholesterol? Harvard heart letter : from Harvard Medical School, 2010, Volume: 20, Issue:12 Topics: Allylamine; Azetidines; Colesevelam Hydrochloride; Diet, Mediterranean; Ezetimibe; Humans; Hydroxyme	2010
[Optimal lipid treatment: possibilities and current limitations]. Der Internist, 2011, Volume: 52, Issue:3 Topics: Anion Exchange Resins; Anticholesteremic Agents; Blood Component Removal; Cardiovascular Diseases; C	2011
Needed: pragmatic clinical trials for statin-intolerant patients. The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Clinical Trials as Topic; Creatine Kinase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H	2011
[Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?]. MMW Fortschritte der Medizin, 2011, Dec-08, Volume: 153, Issue:49-50 Topics: Acute Coronary Syndrome; Amides; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol,	2011
The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial: to believe or not to believe? Journal of the American College of Cardiology, 2012, Jun-05, Volume: 59, Issue:23 Topics: Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholes	2012
Side effects. Niacin for cholesterol and weight problems? TreatmentUpdate, 2000, Volume: 12, Issue:5 Topics: Antiretroviral Therapy, Highly Active; Humans; Hypercholesterolemia; Lipodystrophy; Niacin; Triglyce	2000
Optical coherence tomography findings in nicotinic acid maculopathy. American journal of ophthalmology, 2003, Volume: 135, Issue:6 Topics: Aged; Fluorescein Angiography; Humans; Hypercholesterolemia; Hypolipidemic Agents; Interferometry; L	2003
Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations. Proceedings of the staff meetings. Mayo Clinic, 1956, Jun-27, Volume: 31, Issue:13 Topics: Blood; Cholesterol; Humans; Hypercholesterolemia; Lipids; Niacin; Nicotinic Acids	1956
Some clinical aspects of nicotinic acid therapy in hypercholesterolaemia. Canadian Medical Association journal, 1958, Mar-15, Volume: 78, Issue:6 Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids	1958
Treatment of hypercholesterolemia with nicotinic acid. Circulation, 1958, Volume: 17, Issue:4, Part 1 Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids	1958
Treatment of hypercholesteremia with large oral doses of nicotinic acid: further investigations. The Medical clinics of North America, 1958, Volume: 42, Issue:4 Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids	1958
USE OF nicotinic acid in hypercholesteremia. Journal of the American Medical Association, 1958, Nov-29, Volume: 168, Issue:13 Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids	1958
[Treatment of hypercholesteremia with nicotinic acid]. Ugeskrift for laeger, 1959, Feb-05, Volume: 121, Issue:6 Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids	1959
Jaundice occurring during nicotinic acid therapy for hypercholesteremia. Journal of the American Medical Association, 1959, Aug-22, Volume: 170, Issue:17 Topics: Cholesterol; Hypercholesterolemia; Jaundice; Niacin; Nicotinic Acids	1959
Influence of nicotinic acid on starvation hypercholesteremia in rabbits. Metabolism: clinical and experimental, 1961, Volume: 10 Topics: Animals; Arteriosclerosis; Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids; Rabbits; Star	1961
Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustained-action preparations and report of two cases of jaundice. JAMA, 1961, Aug-26, Volume: 177 Topics: Cholesterol; Hypercholesterolemia; Jaundice; Niacin; Nicotinic Acids	1961
Studies of nicotinic acid use in hypercholesteremia. Changes in hepatic function, carbohydrate tolerance, and uric acid metabolism. Archives of internal medicine, 1961, Volume: 107 Topics: Carbohydrates; Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids; Uric Acid	1961
Treatment of hypercholesteremia by nicotinic acid. Progress report with review of studies regarding mechanism of action. Archives of internal medicine, 1961, Volume: 107 Topics: Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids; Research Report	1961
[Long-term treatment of hypercholesterolemia with nicotinic acid]. Ugeskrift for laeger, 1961, Aug-25, Volume: 123 Topics: Cholesterol; Humans; Hypercholesterolemia; Long-Term Care; Niacin; Nicotinic Acids	1961
[Nicotinic acid treatment in hypercholesterolemia and atheromatosis]. Svenska lakartidningen, 1961, Mar-10, Volume: 58 Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids	1961
The effect of nicotinic acid on hypercholesterolaemia. Canadian Medical Association journal, 1960, Apr-09, Volume: 82 Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids	1960
Comparison of the treatment of hypercholesteremia with nicotinic acid, sitosterol, and safflower oil. American heart journal, 1959, Volume: 58 Topics: Arachidonic Acid; Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids; Safflower Oil;	1959
[On nicotinic acid therapy of hypercholesterolemia]. Zeitschrift fur Kreislaufforschung, 1960, Volume: 49 Topics: Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids	1960
Triparanol and nicotinic acid in the management of hypercholesterolaemia. Australasian annals of medicine, 1962, Volume: 11 Topics: Anticholesteremic Agents; Cardiotonic Agents; Cholesterol; Coronary Disease; Disease Management; Hyp	1962
Pharmacologic agents and lipid metabolism. Geriatrics, 1963, Volume: 18 Topics: Alcohols; Heparin; Hypercholesterolemia; Lipid Metabolism; Niacin; Nicotinic Acids; Thyroxine	1963
Use of nicotinic acid to reduce serum cholesterol and remove tissue cholesterol. Southern medical journal, 1963, Volume: 56 Topics: Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids	1963
Use of nicotinic acid to reduce serum lipid levels. Journal of the American Geriatrics Society, 1962, Volume: 10 Topics: Aluminum; Humans; Hypercholesterolemia; Lipids; Niacin; Nicotinic Acids	1962
[Contribution to preventive cardiology]. Medizinische Klinik, 1963, May-17, Volume: 58 Topics: Coronary Disease; Diet; Fats, Unsaturated; Heparin; Hypercholesterolemia; Ion Exchange Resins; Neomy	1963
[Further research on the hypocholesteremic action of a higher homologue of nicotinic acid: 3-pyridineacetic acid]. Minerva medica, 1963, Jan-27, Volume: 54 Topics: Acetates; Cholesterol; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids; Pyridines; Research	1963
Reduction of plasma cholesterol levels in atherosclerosis by diet and drug treatment. Australasian annals of medicine, 1963, Volume: 12 Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Diet; Diet Therapy; Fats; Humans; Hypercholesterolem	1963
Aluminum nicotinate in the treatment of hypercholesteremia, hyperlipemia, and other elevated lipid levels. Current therapeutic research, clinical and experimental, 1962, Volume: 4 Topics: Aluminum; Aluminum Compounds; Hypercholesterolemia; Hyperlipidemias; Lipids; Niacin; Nicotinic Acids	1962
Hormonal hypercholesterolemia in the dog: influence of niacin, niacinamide, benzmalecene, and cholestyramine resin. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1963, Volume: 112 Topics: Animals; Cholestyramine Resin; Dogs; Hypercholesterolemia; Ion Exchange Resins; Maleates; Niacin; Ni	1963
[Report on a study of the clinical importance of nicotinic acid in the treatment of patients suffering with hypercholesterolemia]. Nederlands tijdschrift voor geneeskunde, 1963, Aug-10, Volume: 107 Topics: Humans; Hypercholesterolemia; Niacin; Nicotinic Acids	1963
Treatment of hypercholesterolemia with aluminum nicotinate. Journal of the American Geriatrics Society, 1962, Volume: 10 Topics: Aluminum; Hypercholesterolemia; Niacin; Nicotinic Acids	1962
Treatment of hypercholesteremia with triparanol and comparison with nicotinic acid. Proceedings of the staff meetings. Mayo Clinic, 1963, Jan-16, Volume: 38 Topics: Alcohols; Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids; Triparanol	1963
[A precis regarding the hypocholesterolemic activities of nicotinic acid and 3-pyridineacetic acid]. Minerva medica, 1963, Jul-04, Volume: 54 Topics: Acetates; Humans; Hypercholesterolemia; Niacin; Nicotinic Acids; Pyridines	1963
[A study of the value of nicotinic acid in the treatment of hypercholesteremia]. Nederlands militair geneeskundig tijdschrift, 1963, Volume: 16 Topics: Humans; Hypercholesterolemia; Lipids; Niacin; Nicotinic Acids	1963
[Combined administration of triparanol and magnesium nicotinate in essential hypercholesterolemia]. Finska lakaresallskapets handlingar, 1962, Volume: 106 Topics: Alcohols; Hypercholesterolemia; Hyperlipoproteinemia Type II; Magnesium; Niacin; Nicotinic Acids; Tr	1962
[The influence of Complamine on serum cholesterol]. Medizinische Monatsschrift, 1963, Volume: 17 Topics: Cholesterol; Hypercholesterolemia; Leadership; Niacin; Nicotinic Acids; Theophylline; Xanthinol Niac	1963
Concepts, theory and treatment of atherosclerosis. Journal of the American Geriatrics Society, 1962, Volume: 10 Topics: Alcohols; Arteriosclerosis; Atherosclerosis; Fats, Unsaturated; Heparin; Hypercholesterolemia; Niaci	1962
ANTI-ATHEROGENIC EFFECTS OF ALUMINUM NICOTINATE IN THE HYPERCHOLESTEROLEMIC CANINE. Surgical forum, 1963, Volume: 14 Topics: Aluminum; Aluminum Compounds; Animals; Arteriosclerosis; Atherosclerosis; Dogs; Hypercholesterolemia	1963
[HORMONAL INTERRELATIONS OF THE SALIVARY GLANDS. THE SALIVARY GLANDS AND THE THYROID. 1. PROTECTION BY SOME PYRIDINES FROM THE EFFECTS OF METHYLTHIOURACIL]. Boletin del Instituto de Estudios Medicos y Biologicos, Universidad Nacional Autonoma de Mexico, 1963, Volume: 21 Topics: Dietary Fats; Hypercholesterolemia; Methylthiouracil; Niacin; Nicotinic Acids; Pathology; Picolines;	1963
EFFECT OF NICOTINIC ACID ON ABNORMAL SERUM LIPIDS. British medical journal, 1964, Jan-18, Volume: 1, Issue:5376 Topics: Child; Cholesterol; Geriatrics; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; Lipids; Lip	1964
ACANTHOSIS NIGRICANS-LIKE LESIONS FROM NICOTINIC ACID. Archives of dermatology, 1964, Volume: 89 Topics: Acanthosis Nigricans; Adenocarcinoma; Diagnosis, Differential; Diethylstilbestrol; Humans; Hyperchol	1964
[TRIPARANOL, L-TRIIODOTHYRONINE AND 3-PYRIDYL ACETIC ACID IN THE CONTROL OF CHOLESTEROLEMIA. A COMPARATIVE STUDY]. Revista medica de Chile, 1963, Volume: 91 Topics: Acetates; Acetic Acid; Arteriosclerosis; Hypercholesterolemia; Niacin; Nicotinic Acids; Triiodothyro	1963
A LONG TERM STUDY OF THE EFFECT OF NICOTINIC ACID MEDICATION ON HYPERCHOLESTEREMIA. The American journal of the medical sciences, 1963, Volume: 246 Topics: Acanthosis Nigricans; Arteriosclerosis; Coronary Disease; Diabetes Mellitus; Geriatrics; Humans; Hyp	1963
[FAMILIAL XANTHOMATOUS HYPERCHOLESTEREMIA]. Coeur et medecine interne, 1963, Volume: 58 Topics: Adrenocorticotropic Hormone; Cortisone; Diagnosis, Differential; Diet; Diet Therapy; Dietary Fats; E	1963
[STUDIES ON THE TREATMENT OF ENDOGENOUS HYPERLIPOPROTEINEMIA WITH BETA-PYRIDYL-CARBINOL]. Klinische Wochenschrift, 1963, Nov-15, Volume: 41 Topics: Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Lipoproteins; Methanol; Niacin	1963
SKIN BREVITIES: VITILIGO. Skin, 1964, Volume: 3 Topics: Humans; Hypercholesterolemia; Niacin; Nicotinic Acids; Theophylline; Vitiligo	1964
[THE USE OF DRUGS IN THE CONTROL OF CHOLESTEROLEMIA]. La Semana medica, 1963, Dec-16, Volume: 123 Topics: Arteriosclerosis; Diet; Hypercholesterolemia; Niacin; Nicotinic Acids; Thyroxine; Toxicology; Triiod	1963
[THE SIGNIFICANCE OF INSUFFICIENT CLEARANCE IN ATHEROGENESIS]. Munchener medizinische Wochenschrift (1950), 1963, Dec-13, Volume: 105 Topics: Arteriosclerosis; Atherosclerosis; Dietary Fats; Glycerides; Heparin; Heparinoids; Hypercholesterole	1963
MANAGEMENT OF HYPERCHOLESTEROLEMIA. GP, 1964, Volume: 29 Topics: Cerebral Hemorrhage; Cholagogues and Choleretics; Coronary Disease; Diet; Diet Therapy; Hypercholest	1964
[PHARMACOLOGICAL STUDIES ON THE PREPARATION "NICATOL"]. Farmatsevtychnyi zhurnal, 1963, Volume: 18 Topics: Arteriosclerosis; Blood Proteins; Cholesterol; Hypercholesterolemia; Lecithins; Lipids; Lipoproteins	1963
[ATHEROSCLEROSIS AND CHOLESTEROLEMIA]. La Semana medica, 1963, Dec-09, Volume: 123 Topics: Arteriosclerosis; Atherosclerosis; Enzyme Inhibitors; Estrogens; Fats, Unsaturated; Heparin; Hyperch	1963
[DRUGS AGAINST HYPERCHOLESTEROLEMIA]. Medicina, 1964, Jul-25, Volume: 44 Topics: Adrenal Cortex Hormones; Arteriosclerosis; Estrogens; Gonadal Steroid Hormones; Heparin; Humans; Hyp	1964
[ON CHOLESTEROL MOBILIZATION IN THE TREATMENT OF XANTHOMA AND ATHEROSCLEROSIS]. Arzneimittel-Forschung, 1963, Volume: 13 Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Drug Therapy; Heparin; Humans; Hypercholesterolemia;	1963
HYPERCHOLESTEREMIA: EFFECTS OF TREATMENT WITH NICOTINIC ACID FOR THREE TO SEVEN YEARS. Diseases of the chest, 1964, Volume: 46 Topics: Biomedical Research; Blood Chemical Analysis; Drug Therapy; Glucose Tolerance Test; Hypercholesterol	1964
THERAPY OF HYPERCHOLESTEROLEMIA. The American journal of digestive diseases, 1964, Volume: 9 Topics: Diet; Diet Therapy; Drug Therapy; Hypercholesterolemia; Neomycin; Niacin; Nicotinic Acids	1964
[COMPLAMINE TREATMENT OF PATIENTS WITH INCREASED SERUM CHOLESTEROL VALUES]. Svenska lakartidningen, 1964, Sep-09, Volume: 61 Topics: Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Hyperlipidemias; Niacin; Nicotinic Acid	1964
THE EFFECTS OF NICOTINIC ACID ON RABBIT HYPERCHOLESTEROLEMIA AND ATHEROGENESIS. Geriatrics, 1965, Volume: 71 Topics: Aorta; Arteriosclerosis; Atherosclerosis; Blood Chemical Analysis; Cholesterol; Diet; Hypercholester	1965
[TREATMENT OF HYPERCHOLESTEREMIA WITH COMPLAMIN (7-/2-HYDROXY-3-(N-2-HYDROXYETHYL-N-METHYLAMINO)-PROPYLTHEOPHYLLINE NICOTINATE)]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1965, May-01, Volume: 20 Topics: Anticholesteremic Agents; Hypercholesterolemia; Niacin; Nicotinic Acids; Theophylline; Xanthinol Nia	1965
ALUMINUM NICOTINATE: A HYPOCHOLESTEREMIC AGENT. Current therapeutic research, clinical and experimental, 1965, Volume: 7 Topics: Aluminum; Aluminum Compounds; Anticholesteremic Agents; Drug Therapy; Hypercholesterolemia; Niacin;	1965
Use of aluminum nicotinate in hypercholesterolemia. Current therapeutic research, clinical and experimental, 1960, Volume: 2 Topics: Aluminum; Aluminum Compounds; Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids	1960
Comparison of effect of nicotinic acid on two different types of hypercholesteremia. Circulation research, 1962, Volume: 11 Topics: Cholesterol; Hypercholesterolemia; Hypothyroidism; Niacin; Nicotinic Acids	1962
[The hypocholesterolemic effect of nicotinic acid in hypercholesterolemia induced by methylthiouracil]. Boletin del Instituto de Estudios Medicos y Biologicos, Universidad Nacional Autonoma de Mexico, 1962, Volume: 20 Topics: Hematologic Diseases; Hypercholesterolemia; Lipid Metabolism Disorders; Methylthiouracil; Niacin; Ni	1962
Hypercholesterolemia. Use of niacin and niacin combinations in therapy. California medicine, 1962, Volume: 96 Topics: Cholesterol; Depression; Estrogens; Humans; Hypercholesterolemia; Jaundice; Niacin; Xanthomatosis	1962
Treatment of hypercholesterolemia in patients with diabetes at a family practice office. Delaware medical journal, 2003, Volume: 75, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Cholesterol, LDL; Comorbidity; Cross-Sectional Studies; Delaware; Di	2003
Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options. American heart journal, 2004, Volume: 148, Issue:1 Suppl Topics: Alanine Transaminase; Aspartate Aminotransferases; Cholesterol, LDL; Clinical Trials as Topic; Creat	2004
Tryptophan metabolism along the kynurenine pathway in diet-induced and genetic hypercholesterolemic rabbits. Clinica chimica acta; international journal of clinical chemistry, 2004, Volume: 350, Issue:1-2 Topics: Animals; Carboxy-Lyases; Hypercholesterolemia; Indoleamine-Pyrrole 2,3,-Dioxygenase; Intestine, Smal	2004
Lipid-lowering drugs. Nursing older people, 2004, Volume: 16, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Ezetimibe; Fatty Acids	2004
Lower cholesterol without statins. Options are available. Mayo Clinic health letter (English ed.), 2006, Volume: 24, Issue:5 Topics: Allylamine; Azetidines; Cholesterol, LDL; Cholinergic Antagonists; Colesevelam Hydrochloride; Ezetim	2006
[Safety and tolerability of nicotinic acid. Results of the multicenter, open, prospective NAUTILUS study]. MMW Fortschritte der Medizin, 2006, May-04, Volume: 148, Issue:18 Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LD	2006
Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. International journal of cardiology, 2008, Feb-29, Volume: 124, Issue:2 Topics: Adipocytes; Analysis of Variance; Animals; Anticholesteremic Agents; Biological Transport; Cholester	2008
[Effect of niacin on adiponectin levels in the adipocytes secretion in rabbits]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2007, Volume: 32, Issue:3 Topics: Adipocytes; Adiponectin; Animals; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol,	2007
[Effect of niacin on HDL-induced cholesterol efflux and LXRalpha expression in adipocytes of hypercholesterolemic rabbits]. Zhonghua xin xue guan bing za zhi, 2007, Volume: 35, Issue:8 Topics: Adipocytes; Animals; Cholesterol; Disease Models, Animal; DNA-Binding Proteins; Hypercholesterolemia	2007
Help for your cholesterol when statins won't do. If you are one of the many, but also one of the few... Harvard men's health watch, 2005, Volume: 9, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA R	2005
Glunicate (LG 13979) protects the arterial wall from cholesterol-induced atherosclerotic changes in the rabbit without affecting plasma lipids. Atherosclerosis, 1984, Volume: 53, Issue:1 Topics: Animals; Aorta; Arteriosclerosis; Blood Coagulation; Cholesterol, Dietary; Dose-Response Relationshi	1984
Severe hypertriglyceridaemia responding to insulin and nicotinic acid therapy. Postgraduate medical journal, 1981, Volume: 57, Issue:670 Topics: Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypercholesterolemia;	1981
Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Archives of internal medicine, 1994, Jul-25, Volume: 154, Issue:14 Topics: Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins; Lovastatin; Niacin	1994
[Enduracin--a nicotinic acid preparation in the treatment of hypercholesterolemia]. Kardiologiia, 1993, Volume: 33, Issue:11 Topics: Clinical Trials as Topic; Delayed-Action Preparations; Hemostasis; Humans; Hypercholesterolemia; Hyp	1993
Over-the-counter niacin. JAMA, 1994, Mar-02, Volume: 271, Issue:9 Topics: Delayed-Action Preparations; Humans; Hypercholesterolemia; Niacin; Nonprescription Drugs; Patient Co	1994
Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: preliminary experience. Postgraduate medical journal, 1993, Volume: 69, Issue:810 Topics: Aged; Bezafibrate; Cholesterol, HDL; Drug Administration Schedule; Drug Therapy, Combination; Female	1993
Combination drug therapy for hypercholesterolemia. The trade-off between cost and simplicity. Archives of internal medicine, 1993, Aug-09, Volume: 153, Issue:15 Topics: Aged; Algorithms; Anticholesteremic Agents; Decision Trees; Drug Costs; Drug Therapy, Combination; F	1993
New guidelines for managing hypercholesterolemia. National Cholesterol Education Program. American pharmacy, 1993, Volume: NS33, Issue:7 Topics: Algorithms; Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Female; Humans; Hypercholest	1993
Severe reversible hyperglycemia as a consequence of niacin therapy. Archives of internal medicine, 1993, Sep-13, Volume: 153, Issue:17 Topics: Humans; Hypercholesterolemia; Hyperglycemia; Male; Middle Aged; Niacin	1993
Choice of cholesterol-lowering drugs. The Medical letter on drugs and therapeutics, 1993, Mar-05, Volume: 35, Issue:891 Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Huma	1993
Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. The American journal of cardiology, 1993, Apr-01, Volume: 71, Issue:10 Topics: Age Factors; Anticholesteremic Agents; Cholesterol; Humans; Hypercholesterolemia; Lovastatin; Middle	1993
Transient focal hepatic defects related to sustained-release niacin. Journal of clinical gastroenterology, 1993, Volume: 16, Issue:3 Topics: Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Fatty Liver; Female; Hum	1993
Niacin treatment of hypercholesterolemia in children. Pediatrics, 1993, Volume: 92, Issue:1 Topics: Adolescent; Child; Child, Preschool; Cholesterol, LDL; Female; Humans; Hypercholesterolemia; Male; N	1993
Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. The American journal of medicine, 1996, Volume: 100, Issue:2 Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Colestipol; Coronary Disease; Female; Gemfibrozil;	1996
[Effect of enduracin on the activity of a cholesterol ester transfer protein in blood plasma of people with hypercholesteremia]. Biulleten' eksperimental'noi biologii i meditsiny, 1996, Volume: 121, Issue:2 Topics: Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; F	1996
[Effects of enduracin on the level of cholesterol in flying personnel]. Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine, 1997, Volume: 31, Issue:3 Topics: Adult; Aerospace Medicine; Anticholesteremic Agents; Cholesterol; Humans; Hypercholesterolemia; Lipo	1997
Macular edema associated with nicotinic acid (niacin) JAMA, 1998, Jun-03, Volume: 279, Issue:21 Topics: Humans; Hypercholesterolemia; Macular Edema; Male; Middle Aged; Niacin	1998
Medical nutrition therapy lowers serum cholesterol and saves medication costs in men with hypercholesterolemia. Journal of the American Dietetic Association, 1998, Volume: 98, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; California; Cholesterol; Dietary Services; Health Care Costs;	1998
Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. The American journal of cardiology, 1998, Dec-17, Volume: 82, Issue:12A Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Female; Humans; Hypercholesterol	1998
[Drug clinics. How I treat a patient with a low concentration of HDL cholesterol]. Revue medicale de Liege, 1998, Volume: 53, Issue:12 Topics: Cholesterol, HDL; Cholesterol, LDL; Exercise Therapy; Heart Diseases; Humans; Hypercholesterolemia;	1998
Immunoadsorption and dextran sulfate cellulose LDL-apheresis for severe hypercholesterolemia: the Rogosin Institute experience 1982-1992. Transfusion science, 1993, Volume: 14, Issue:3 Topics: Adult; Aged; Blood Component Removal; Child; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Co	1993
Ask the doctor: I have very high cholesterol that isn't in the target range, even with high doses of statins. I hate to take any more pills. Any advice? Harvard heart letter : from Harvard Medical School, 2000, Volume: 10, Issue:11 Topics: Anticholesteremic Agents; Drug Therapy, Combination; Humans; Hypercholesterolemia; Niacin	2000
A new niacin. Vitamin with an HDL kick. U.S. news & world report, 2001, Apr-16, Volume: 130, Issue:15 Topics: Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Humans; Hypercholesterolemia; Niaci	2001
Choice of lipid-regulating drugs. The Medical letter on drugs and therapeutics, 2001, May-28, Volume: 43, Issue:1105 Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Intera	2001
Niacin versus niacinamide. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1992, Oct-01, Volume: 147, Issue:7 Topics: Humans; Hypercholesterolemia; Niacin; Niacinamide	1992
Niacin versus niacinamide. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1992, Oct-01, Volume: 147, Issue:7 Topics: Humans; Hypercholesterolemia; Niacin; Niacinamide	1992
Megavitamin and megamineral therapy in childhood. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1992, Jun-15, Volume: 146, Issue:12 Topics: Flushing; Humans; Hypercholesterolemia; Niacin; Niacinamide	1992
Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis, 1992, Volume: 95, Issue:1 Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Hypercholesterole	1992
A stable isotope dilution mass spectrometric assay for the major urinary metabolite of PGD2. Advances in prostaglandin, thromboxane, and leukotriene research, 1991, Volume: 21A Topics: Asthma; Bronchoalveolar Lavage Fluid; Histamine; Humans; Hydroxyprostaglandin Dehydrogenases; Hyperc	1991
Megavitamin and megamineral therapy in childhood. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1991, Jul-15, Volume: 145, Issue:2 Topics: Acanthosis Nigricans; Humans; Hypercholesterolemia; Niacin; Orthomolecular Therapy	1991
Niacin caution. Postgraduate medicine, 1991, Volume: 89, Issue:4 Topics: Humans; Hypercholesterolemia; Niacin	1991
Changes in vitamin and mineral intakes and serum concentrations among free-living men on cholesterol-lowering diets: the Dietary Alternatives Study. The American journal of clinical nutrition, 1991, Volume: 53, Issue:4 Topics: Ascorbic Acid; beta Carotene; Carotenoids; Diet; Dietary Fats; Energy Intake; Folic Acid; Humans; Hy	1991
Unstable myocardial ischemia after the initiation of niacin therapy. The American journal of cardiology, 1991, Apr-15, Volume: 67, Issue:9 Topics: Aged; Angina Pectoris; Angina, Unstable; Cholesterol, HDL; Coronary Disease; Electrocardiography; Hu	1991
Delirium and lactic acidosis caused by ethanol and niacin coingestion. The American journal of emergency medicine, 1991, Volume: 9, Issue:4 Topics: Acid-Base Equilibrium; Acidosis, Lactic; Adult; Alcoholic Intoxication; Delirium; Humans; Hyperchole	1991
Hypercholesterolemia: the cost of treatment in perspective. Southern medical journal, 1990, Volume: 83, Issue:12 Topics: Adult; Aged; Child; Cost-Benefit Analysis; Dietary Fiber; Electrocardiography; Evaluation Studies as	1990
Hypercholesterolemia after cardiac transplantation in children. The American journal of cardiology, 1990, Dec-01, Volume: 66, Issue:19 Topics: Adolescent; Child; Child, Preschool; Female; Heart Transplantation; Humans; Hypercholesterolemia; In	1990
Managing lipid disorders. Iowa medicine : journal of the Iowa Medical Society, 1990, Volume: 80, Issue:4 Topics: Aspirin; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Hypercholesterolemia; Niaci	1990
Nicotinic acid and hypercholesterolemia. Archives of internal medicine, 1990, Volume: 150, Issue:7 Topics: Drug Administration Schedule; Humans; Hypercholesterolemia; Niacin	1990
Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. The Journal of clinical investigation, 1990, Volume: 86, Issue:3 Topics: Adult; Aged; Cholesterol; Colestipol; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Metabo	1990
Controlling cholesterol with drugs. The American journal of nursing, 1989, Volume: 89, Issue:12 Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Humans; Hypercholesterole	1989
Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Annals of internal medicine, 1989, Aug-01, Volume: 111, Issue:3 Topics: Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Hepatic Encephalopathy;	1989
[Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1989, Mar-10, Volume: 109, Issue:7-8 Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Norway; Probuc	1989
Hypercholesterolemia: new values, new strategies. Hospital practice (Office ed.), 1986, Jan-30, Volume: 21, Issue:1A Topics: Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Colestipol; Coronary Disease; Energy Intake; Fe	1986
Treating hyperlipidemia, Part III: Drug therapy. Geriatrics, 1987, Volume: 42, Issue:8 Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias	1987
Hypocholesterolemic effects of nicotinic acid and chromium supplementation. The Journal of family practice, 1988, Volume: 27, Issue:6 Topics: Cholesterol; Chromium; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Middle Aged;	1988
Current and new therapy for hypercholesterolemia. The Journal of the American Osteopathic Association, 1988, Volume: 88, Issue:7 Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin;	1988
Effectiveness of individualized long-term therapy with niacin and probucol in reduction of serum cholesterol. The Journal of family practice, 1988, Volume: 26, Issue:2 Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Combined Modality Therapy; Drug Therapy, Combination; Fe	1988
Lovastatin alone and in combination for treatment of primary hypercholesterolemia. Progress in clinical and biological research, 1988, Volume: 255 Topics: Adult; Aged; Anion Exchange Resins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; F	1988
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Archives of internal medicine, 1988, Volume: 148, Issue:1 Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Diet	1988
Current pharmacologic treatment of elevated serum cholesterol. Circulation, 1987, Volume: 76, Issue:3 Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co	1987
[Experimental hyperlipoproteinemia and arteriosclerosis in minipigs--effect of various drugs]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1986, Jul-15, Volume: 41, Issue:14 Topics: Animals; Arteries; Arteriosclerosis; Cholesterol; Hypercholesterolemia; Hyperlipoproteinemias; Hypol	1986
Comparison of six pharmacologic regimens for hypercholesterolemia. The American journal of cardiology, 1987, Apr-01, Volume: 59, Issue:8 Topics: Adult; Aged; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia;	1987
[Drugs in hyperlipidemia]. Nederlands tijdschrift voor geneeskunde, 1987, Sep-05, Volume: 131, Issue:36 Topics: Cholestyramine Resin; Clofibrate; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemi	1987
Nicotinic acid-induced fulminant hepatic failure. Journal of clinical gastroenterology, 1987, Volume: 9, Issue:5 Topics: Chemical and Drug Induced Liver Injury; Hepatic Encephalopathy; Humans; Hypercholesterolemia; Liver	1987
The influence of hypercholesterolaemia on the adrenal uptake and metabolic handling of 131I-6 beta-iodomethyl-19-norcholesterol (NP-59). Nuclear medicine communications, 1986, Volume: 7, Issue:8 Topics: 19-Iodocholesterol; Adrenal Cortex; Animals; Bile; Cholesterol; Colestipol; Disease Models, Animal;	1986
[Changes in lysozyme activity in hyperlipidemia and atherosclerosis in animals]. Nauchnye doklady vysshei shkoly. Biologicheskie nauki, 1985, Issue:4 Topics: Adjuvants, Immunologic; Animals; Arteriosclerosis; Enzyme Activation; Hypercholesterolemia; Hyperlip	1985

niacin and Elevated Cholesterol

Research Excerpts

Research

Studies (241)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Coronary or Non-coronary Revascularisation

Major Coronary Events

Major Vascular Event

Mortality

Stroke

Prostaglandin I Metabolite (PGI-M)

Urinary 11-dehydrothromboxane B2 (11-dTxB2)

Prostaglandin I Metabolite (PGI-M)

Urinary 11-Dehydrothromboxane B2 (11-dTxB2)

Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12

Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12

Percent Change From Baseline in Triglycerides at Week 12

Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries

Multiple Combined Events ( Cardiovascular and Cerebrovascular Events as Well as Myocardial Revascularization)

Reviews

Trials

Other Studies